Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)”

209 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 209 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06436144
What this trial is testing

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIB+1 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 93
Early research (Phase 1)Active Not RecruitingNCT04141644
What this trial is testing

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

Who this might be right for
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
University of Utah 24
Not applicableStudy completedNCT02285361
What this trial is testing

GIOTRIF rPMS in Korean Patients With NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 1,272
Large-scale testing (Phase 3)Active Not RecruitingNCT05870319
What this trial is testing

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 376
Not applicableStudy completedNCT02777658
What this trial is testing

PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 169
Post-approval studies (Phase 4)Study completedNCT02514174
What this trial is testing

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Who this might be right for
Carcinoma, Non-Small-Cell LungErbB Receptors
Boehringer Ingelheim 25
Not applicableNot Yet RecruitingNCT05698264
What this trial is testing

A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationImmune Checkpoint Inhibitor
Nir Peled 50
Testing effectiveness (Phase 2)UnknownNCT02274337
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 100
Early research (Phase 1)Study completedNCT02374645
What this trial is testing

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Hutchison Medipharma Limited 64
Large-scale testing (Phase 3)Study completedNCT00874419
What this trial is testing

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

Who this might be right for
Non-small Cell Lung Cancer
Tongji University 165
Not applicableStudy completedNCT00898924
What this trial is testing

Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Alliance for Clinical Trials in Oncology 60
Early research (Phase 1)Active Not RecruitingNCT06685718
What this trial is testing

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerLung CancerNSCLC+3 more
BeOne Medicines 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07329322
What this trial is testing

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 60
Early research (Phase 1)Study completedNCT02113813
What this trial is testing

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Non-Small-Cell Lung Cancer (NSCLC)Epidermal Growth Factor Receptor Mutations
Astellas Pharma Global Development, Inc. 133
Large-scale testing (Phase 3)Looking for participantsNCT04853342
What this trial is testing

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Who this might be right for
Non-small Cell Lung Carcinoma
Allist Pharmaceuticals, Inc. 318
Testing effectiveness (Phase 2)Looking for participantsNCT06951464
What this trial is testing

BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan University 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT05546866
What this trial is testing

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 51
Testing effectiveness (Phase 2)Ended earlyNCT02192697
What this trial is testing

An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Non-small Cell Lung Cancer
Astellas Pharma Inc 124
Not applicableTemporarily pausedNCT05421936
What this trial is testing

Osimertinib for NSCLC With Uncommon EGFR Mutations

Who this might be right for
Carcinoma, Non-Small-Cell LungGenes, erbB-1
Sheba Medical Center 100
Early research (Phase 1)Study completedNCT01859026
What this trial is testing

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Who this might be right for
Lung CancerNon-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 43
Load More Results